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BACKGROUND AND PURPOSE
At present there are no small molecule inhibitors that show strong selectivity for the Na+/Ca2+ exchanger (NCX). Hence, we
studied the electrophysiological effects of acute administration of ORM-10103, a new NCX inhibitor, on the NCX and L-type
Ca2+ currents and on the formation of early and delayed afterdepolarizations.
EXPERIMENTAL APPROACH
Ion currents were recorded by using a voltage clamp technique in canine single ventricular cells, and action potentials were
obtained from canine and guinea pig ventricular preparations with the use of microelectrodes.
KEY RESULTS
ORM-10103 significantly reduced both the inward and outward NCX currents. Even at a high concentration (10 μM),
ORM-10103 did not significantly change the L-type Ca2+ current or the maximum rate of depolarization (dV/dtmax), indicative
of the fast inward Na+ current. At 10 μM ORM-10103 did not affect the amplitude or the dV/dtmax of the slow response
action potentials recorded from guinea pig papillary muscles, which suggests it had no effect on the L-type Ca2+ current.
ORM-10103 did not influence the Na+/K+ pump or the main K+ currents of canine ventricular myocytes, except the rapid
delayed rectifier K+ current, which was slightly diminished by the drug at 3 μM. The amplitudes of pharmacologically- induced
early and delayed afterdepolarizations were significantly decreased by ORM-10103 (3 and 10 μM) in a
concentration-dependent manner.
CONCLUSIONS AND IMPLICATIONS
ORM-10103 is a selective inhibitor of the NCX current and can abolish triggered arrhythmias. Hence, it has the potential to
be used to prevent arrhythmogenic events.
LINKED ARTICLE
This article is commented on by Terracciano and Hancox, pp. 765–767 of this issue. To view this commentary visit
http://dx.doi.org/10.1111/bph.12299
Abbreviations
DAD, delayed afterdepolarization; dV/dtmax, maximum upstroke velocity of action potential; EAD, early
afterdepolarization; ICaL, L-type calcium current; IK1, inward rectifier potassium current; IKr, rapid component of the
delayed rectifier potassium current; INa, sodium current; INCX, Na+/Ca2+ exchanger current; Ip, Na+/K+ pump current; Ito,
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Introduction
The Na+/Ca2+ exchanger (NCX) (Alexander et al., 2011) is con-
sidered to be a major regulator of Ca2+ homeostasis in the
myocardium (Bers, 2000; 2002). In the forward mode, NCX is
known to extrude Ca2+ from the cell to the extracellular space
during diastole at relatively low free cytoplasmic Ca2+ con-
centrations and negative transmembrane potential. Because
the extrusion of one Ca2+ is coupled with the entry of 3 Na+
into the cell, the forward mode of the NCX is accompanied
by a net inward current; when the intracellular Ca2+ level is
elevated, this can cause substantial depolarization, leading to
early afterdepolarization (EAD) and delayed afterdepolariza-
tion (DAD) (Venetucci et al., 2007). EAD and DAD are gener-
ally thought to play important roles in arrhythmogenesis
(Roden, 1996; Volders et al., 2000), especially under condi-
tions of decreased K+ conductance, as in heart failure
(Pogwizd et al., 2001). It has been speculated, therefore, that
specific blockers of NCX have the potential to be antiarrhyth-
mic in dysrhythmias associated with Ca2+ overload (Pogwizd
and Bers, 2002; Pogwizd, 2003). This hypothesis has not yet
been tested directly, as the NCX inhibitors available also
decrease the L-type Ca2+ current (ICaL) which in turn is known
to decrease the intracellular Ca2+ load, thereby indirectly
changing the magnitude of NCX. The effects of NCX blockers
KB-R7943 and SEA-0400 were recently reported. Both of these
drugs are effective inhibitors of NCX, even in submicromolar
concentrations, and they have been demonstrated to reduce
the incidence of ischaemia/reperfusion-related arrhythmias
induced by a Ca2+ overload (Elias et al., 2001) and to decrease
the pharmacologically-induced EAD and DAD in canine ven-
tricular preparations (Nagy et al., 2004). However, results
from other studies have indicated that KB-R7943 and SEA-
0400 also inhibit the ICaL (Tanaka et al., 2002; Birinyi et al.,
2005), which makes the interpretation of their antiarrhyth-
mic effect somewhat uncertain. In the present study, we
investigated the effects of ORM-10103 (chemical structure
shown in Figure 1), another newly developed and specific
NCX inhibitor, on the NCX current, ICaL, INa, Na+/K+ pump (Ip)
and K+ currents of canine ventricular myocytes, and on the
formation of EAD and DAD in canine ventricular muscle and
Purkinje fibres.
Methods
All experiments were conducted in compliance with the
Guide for the Care and Use of Laboratory Animals (USA NIH
Publication No. 85-23, revised 1996) and conformed to Direc-
tive 2010/63/EU of the European Parliament. The protocols
were approved by the Ethical Committee for the Protection of
Animals in Research at the University of Szeged, Szeged,
Hungary (Approval No. I-74-9-2009).
For voltage clamp and conventional microelectrode
experiments, adult mongrel dogs of either sex weighing
8–16 kg were used. Following sedation (xylazine, 1 mg·kg−1,
i.v.) and thiopental (30 mg·kg−1, i.v.)-induced anaesthesia,
each heart was rapidly removed through a right lateral thora-
cotomy and immediately rinsed in oxygenated modified
Locke’s solution containing (in mM): Na+ 140, K+ 4, Ca2+ 1.0,
Mg2+ 1, Cl− 126, HCO3− 25 and glucose 11. The pH of the
solution, when gassed with 95% O2 and 5% CO2 at 37°C,
ranged from 7.35 to 7.45.
Voltage clamp measurements
Cell isolation. Ventricular myocytes were enzymatically dis-
sociated from the canine hearts. A portion of the left ven-
tricular wall containing an arterial branch large enough to
cannulate was then perfused in a modified Langendorff appa-
ratus at a pressure of 60 cmH2O, with solutions in the follow-
ing sequence: (i) isolation solution supplemented with CaCl2
(1.25 mM) for 10 min; (ii) isolation solution for another
10 min; (iii) isolation solution (150 mL) containing colla-
genase (type I, 0.33 mg·mL−1; Sigma Chemical, St. Louis, MO,
USA) (10 min). Protease (type XIV, 0.04 mg·mL−1; Sigma
Chemical) was added to the final perfusate and another
15–20 min of digestion was allowed. The isolation solution
(Ca2+ free) was Eagle’s Minimum Essential Medium, Joklik
modification (Sigma Chemical), supplemented with (in mM)
HEPES 10 and NaHCO3 4.4 (pH 7.2, adjusted with NaOH).
Portions of the left ventricular wall, judged to be well-
digested, were diced into small pieces in isolation solution
supplemented with CaCl2 (1.25 mM) for 15 min. These tissue
samples were then gently agitated in a small beaker to dis-
lodge single myocytes from the extracellular matrix. The
resulting cell suspension contained a mixture of subepicar-
dial, midmyocardial and subendocardial myocytes. Through-
out the entire isolation procedure, solutions were gassed with
100% O2, while their temperature was maintained at 37°C.
Myocytes were allowed to settle to the bottom of the beaker
for 10 min, after which half of the supernatant was replaced
with fresh solution. This procedure was repeated three times.
Myocytes placed in isolation solution supplemented with
CaCl2 (1.25 mM) were maintained at 12–14°C before the
experiment.
Experimental technique. One drop of cell suspension was
placed in a transparent recording chamber mounted on the
stage of an inverted microscope (TMS; Nikon, Tokyo, Japan),
and individual myocytes were allowed to settle and adhere to
the chamber bottom for at least 5 min before superfusion was
initiated and maintained by gravity. Only rod-shaped cells
with clear striations were used. HEPES-buffered Tyrode’s solu-
tion (composition in mM: NaCl 144, NaH2PO4 0.33, KCl 4.0,
CaCl2 1.8, MgCl2 0.53, glucose 5.5, HEPES 5.0, at pH of 7.4)
served as the normal superfusate.
Micropipettes were fabricated from borosilicate glass
capillaries (Clark Electromedical Instruments, Pangbourne,
Reading, UK), using a P-97 Flaming/Brown micropipette
puller (Sutter Co, Novato, CA, USA), and had a resistance of
Figure 1
Chemical structure of ORM-10103.
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1.5–2.5 MΩ when filled with pipette solution. The membrane
currents were recorded with Axopatch-1D or Axopatch-200B
amplifiers (Axon Instruments, Union City, CA, USA) by
means of the whole cell configuration of the patch clamp
technique. After the establishment of high (1–10 GΩ) resist-
ance seals by gentle suction, the cell membrane beneath the
tip of the electrode was disrupted by further suction or by
applying 1.5 V electrical pulses for 1–5 ms. The membrane
currents were digitized with a 333 kHz analogue to digital
converter (Digidata 1200; Axon Instruments) under software
control (pClamp 8.0; Axon Instruments). The results were
analysed by using software programs purchased from Axon
(pClamp 8.0). As the rundown of ICaL and IKs currents is com-
monly seen during the measurements, the current level was
monitored during the initial equilibration period and also at
the end of the measurements when a washout period of at
least 10 min was applied in order to draw a distinction
between drug effect and rundown of the current. The cells, in
which excessive rundown was observed, were omitted from
the analyses. Experiments were carried out at 37°C.
Measurement of NCX current. For the measurement of the
Na+/Ca2+ exchanger current (NCX), the method of Hobai et al.
(1997) was applied, in which special K+-free bath and pipette
solutions were used (see below) in order to block the Na+,
Ca2+, K+-currents and the Na+/K+ pump current. The I-V
(current–voltage) relationship of Na+/Ca2+ exchanger current
was measured through the use of ramp pulses at 20 s inter-
vals. The ramp pulse initially led to depolarization from the
holding potential of −40 mV to 60 mV with a rate of
100 mV·s−1, then to hyperpolarization to −100 mV, and depo-
larization back to the holding potential. The descending limb
of the ramp was utilized to plot the I-V curve.
Compositions of solutions used (in mM). K+-free bath solu-
tion: NaCl 135, CsCl 10, CaCl2 1, MgCl2 1, BaCl2 0.2, NaH2PO4
0.33, TEACl 10, HEPES 10, glucose 10 and ouabain 20 μM,
nisoldipine 1 μM, lidocaine 50 μM, at pH 7.4.
Pipette solution: CsOH 140, aspartic acid 75, TEACl 20,
MgATP 5, HEPES 10, NaCl 20, EGTA 20, CaCl2 10 (pH
adjusted to 7.2 with CsOH).
The experimental protocol was as follows (Figure 2):
• The whole cell configuration was established in HEPES-
buffered Tyrode’s solution
• The control I-V curve was recorded in the special K+-free
bath solution after 8–10 min from establishing whole cell
configuration
• After 6–10 min of incubation, the I-V relationship was
recorded in the presence of ORM-10103
• At the end of the experiments, the Ni2+-insensitive current
was measured by the application of 10 mM NiCl2
The NCX current was defined as the Ni2+-sensitive current,
that is, the trace recorded in the presence of 10 mM NiCl2
subtracted from that measured in the absence of NiCl2. In
separate experiments, the effect of ORM-10103 on the Ni2+-
insensitive current was also tested.
Measurement of ICaL. The ICaL was recorded in HEPES-
buffered Tyrode’s solution supplemented with 3 mM
4-aminopyridine. A special solution was used to fill the
micropipettes (composition in mM: CsOH 110, CsCl 20,
TEACl 10, MgATP 5, EGTA 5, HEPES 10, GTP 0.1; pH was
adjusted to 7.2 by aspartic acid). ICaL was evoked by 400 ms
long depolarizing voltage pulses to various test potentials
ranging from −35 to +55 mV. The holding potential was
Figure 2
Determination of NCX current in canine ventricular myocytes. (A) Recording obtained with the voltage protocol shown in the inset with normal
Tyrode’s solution. (B) The current trace after blockade of Na+, Ca2+, K+ and Na+/K+ pump currents. (C) The current trace after superfusion with 1 μM
ORM-10103. (D) The current trace at the end of the measurements after the application of 10 mM NiCl2. On the right, the control NCX current
is shown, which is obtained by subtracting trace D from trace B. The NCX current in the presence of 1 μM ORM-10103 is obtained by subtracting
trace D from trace C. Note the difference in the intensity-time calibration in the left and right panels.
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−80 mV. A short prepulse of −40 mV served to inactivate Na+
current. The amplitude of the ICaL was defined as the differ-
ence between the peak inward current at the beginning of the
pulse and the current at the end of the pulse.
Measurement of K+ currents. The inward rectifier (IK1), tran-
sient outward (Ito), rapid (IKr) and slow (IKs) delayed rectifier
potassium currents were recorded in HEPES-buffered Tyrode’s
solution. The compositions of the pipette solution (in mM)
were the following: KOH 110, KCl 40, K2ATP 5, MgCl2 5,
EGTA 5 and HEPES 10 (pH was adjusted to 7.2 by aspartic
acid). Nisoldipine 1 μM was added to the external solution to
eliminate ICaL. When IKr was recorded, IKs was inhibited by
using the selective IKs blocker HMR 1556 (0.5 μM). During IKs
measurements, IKr was blocked by 0.1 μM dofetilide. The cur-
rents were activated by applying depolarizing voltage pulses
as shown by insets in Figure 7.
Measurement of Na+/K+ pump current. Steady-state current at
−30 mV was recorded in control conditions and in the pres-
ence of ORM-10103. After 5–7 min incubation with ORM-
10103, the normal external solution (composition in mM:
NaCl 135, CsCl 2, KCl 5, MgCl2 1, CdCl2 0.2, BaCl2 2, HEPES
5, glucose 10, pH 7.4 by NaOH) was replaced by K+-free
solution. The Na+/K+ pump current (Ip) was defined as the
difference between currents measured in 5 and 0 mM K+ con-
taining solutions. The compositions of the pipette solution
(in mM) were as follows: CsOH 100, NaCl 30, MgATP 5,
MgCl2 2, TEACl 20, EGTA 5, HEPES 10 and glucose 10 (pH was
adjusted to 7.2 by aspartic acid).
Conventional microelectrode measurements
The same adult mongrel dogs of either sex weighing 8–16 kg
were used. Purkinje strands obtained from both ventricles
and right ventricular papillary muscle tips were mounted
individually in a tissue chamber superfused with oxygenated
Locke’s solution at 37°C. Each preparation was stimulated
(Hugo Sachs Elektronik stimulator type 215/II, March-
Hugstetten, Germany) initially at a constant cycle length of
1000 ms (frequency 1 Hz), with rectangular constant current
pulses of 2 ms in duration. The current pulses were isolated
from ground and delivered through bipolar platinum elec-
trodes in contact with the preparations. At least 1 h was
allowed for each preparation to equilibrate during continu-
ous superfusion with modified Locke’s solution, warmed to
37°C before the experimental measurements commenced.
Transmembrane potentials were recorded with the use of
conventional 5–20 MΩ, 3 M KCl-filled microelectrodes con-
nected to the input of a high-impedance electrometer (Bio-
logic Amplifier VF 102, Claix, France). The first derivative of
transmembrane potential (dV/dtmax) was obtained electroni-
cally with a Biologic DV-140 (Claix, France) differentiator
designed and calibrated to give a linear response over the
range between 10 and 1000 V·s−1. In each experiment, the
baseline action potential characteristics were first determined
during continuous pacing at 1 Hz (on Purkinje fibres, con-
tinuous pacing at 2 Hz), and then when the pacing cycle
length was sequentially varied from 300 to 5000 ms. The
25th action potential was measured at each cycle length, and
the cycle length was then changed so that quasi-steady-state
frequency–response relationships could be generated rapidly.
The preparations were next superfused with the drug for
40–60 min before the pacing protocol was repeated and the
parameters were measured again. Efforts were made to main-
tain the same impalement throughout each experiment. If an
impalement became dislodged, however, electrode adjust-
ment was attempted, and if the action potential characteris-
tics of the re-established impalement deviated by less than
5% from those of the previous measurement, the experiment
was continued. When this 5% limit was exceeded, the experi-
ment was terminated and all the data involved were excluded
from the analyses.
Recording of slow response action potentials
Adult male guinea pigs of either sex weighing 150–200 g were
administered an anticoagulant, sodium heparin, and anaes-
thetized with 30 mg·kg−1 thiopental after sedation (xylazine,
1 mg·kg−1). The hearts were rapidly removed through a right
lateral thoracotomy and immediately rinsed in ice-cold
Krebs–Henseleit solution (contents in mM: NaCl 118.5, KCl
4.0, CaCl2 2.0, MgSO4 1.0, NaH2PO4 1.2, NaHCO3 25.0, glucose
10.0). The pH of this solution was set to 7.35 ± 0.05 when
saturated with a mixture of 95% O2 and 5% CO2. After exci-
sion, the right or left ventricular papillary muscle prepara-
tions were immediately mounted in a 40 mL tissue chamber,
and initially perfused with normal Krebs–Henseleit solution.
The preparations were stimulated continuously with
an electrostimulator (PW-01; Experimetria Ltd., Budapest,
Hungary) by means of constant rectangular voltage pulses,
1 ms in duration, delivered through a pair of bipolar plati-
num electrodes at a frequency of 1 Hz. Action potentials were
recorded with a conventional microelectrode technique.
Sharp microelectrodes, with a tip resistance of 10–20 MΩ
when filled with 3 M KCl, were connected to the amplifier
(Biologic Amplifier, model VF 102). The voltage output from
the amplifier was sampled with an AD converter (NI 6025;
Unisip Ltd., Budapest, Hungary). The action potential ampli-
tude and maximum rate of depolarization were obtained with
Evokewave v1.49 software (Unisip Ltd). Each preparation was
allowed to equilibrate in normal Krebs–Henseleit solution at
37°C for at least 30 min.
Slow response action potentials were established in modi-
fied Krebs–Henseleit solution containing 25 mM KCl, supple-
mented with 100 μM BaCl2 to inhibit IK1 and with 1 μM
forskolin to increase ICaL. The dV/dtmax values in the interval
5–20 V·s−1 and amplitudes of at least 60 mV were accepted;
data from experiments in which these levels were not met
were discarded.
The nomenclature of NCX used conforms to the BJP’s
Guide to Receptor and Channels (Alexander et al., 2011).
With the exception of ORM-10103 (from Orion Pharma,
Espoo, Finland), nisoldipine (gift from Bayer AG, Leverkusen,
Germany) and strophanthin-G (from BDH Chemicals Ltd,
Poole, England), all chemicals were purchased from Sigma-
Aldrich Fine Chemicals (St. Louis, MO, USA).
Statistics
All data are expressed as means ± SEM. Statistical analysis was
performed with Student’s t-test for paired data. The results
were considered statistically significant when P was <0.05.
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Results
Effects of ORM-10103 on the outward and
inward NCX current
The experimental protocol applied to measure the NCX
current is presented in Figure 2. Part A depicts a current
recording in the presence of normal Tyrode’s solution during
the voltage ramp pulse illustrated in the top right corner,
while part B illustrates a current recording after blocking Na+,
Ca2+, K+ and Na+/K+ pump currents. In part C, 1 μM ORM-
10103 was applied and the current was recorded with the
same voltage pulse. Finally, 10 mM NiCl2 was added to
the tissue bath to block the NCX current completely and the
resulting recording (part D) was subtracted from the control
recording (to give traces B–D) and from the ORM-10103
recording (to give traces C–D). It is clear from Figure 2 that
the Ni2+-sensitive current, that is, the NCX current, was mark-
edly reduced by 1 μM ORM-10103. In three separate experi-
ments, after the Ca2+, Na+, K+, Na+/K+ pump currents and also
INCX were blocked, application of 10 μM ORM-10103 did not
change the Ni2+-insensitive current (not shown). These latter
measurements indicate that the current reduced by ORM-
10103 was indeed the NCX current and not a Ni2+-insensitive
leakage current.
Figures 3 and 4 demonstrate that both the outward and
the inward NCX currents were considerably reduced by ORM-
10103 in a concentration-dependent manner. The effect in
the outward direction was statistically significant in the
potential range between 0 and 60 mV in the presence of
ORM-10103 concentrations higher than 0.5 μM (Figure 4A,
right panel). The blockade of the inward NCX current by
ORM-10103 was also significant at concentrations higher
than 0.5 μM (Figure 4A, left panel). The estimated EC50 values
for the inward and outward NCX currents were 780 and
960 nM respectively (Figure 4B).
Lack of effect of ORM-10103 on the L-type
inward calcium, inward sodium and outward
potassium currents
The possible effect of ORM-10103 on the L-type inward
calcium current was also studied in canine ventricular myo-
cytes. These experiments clearly revealed that even at a high
(10 μM) concentration, ORM-10103 did not influence sig-
nificantly ICaL (Figure 5A). After washout of the drug the
current slightly decreased, further showing that the smaller
average value measured after application of ORM-10103 is
due to a slight rundown of the current. Nifedipine at 10 μM
almost completely blocked the current, indicating that the
recorded current was ICaL (Figure 5A). The effect of ORM-
10103 on the inactivation kinetics was also investigated. The
inactivation time constant was not significantly changed by
10 μM ORM-10103 (40.0 ± 4.6 ms vs. 35.0 ± 5.5 ms at 0 mV,
n = 8, n.s.). The effect of ORM-10103 on the inward sodium
current was assessed by measuring the dV/dtmax in the
canine right ventricular papillary muscle, by use of the con-
ventional microelectrode technique. At the high concentra-
tion of 10 μM, ORM-10103 did not change dV/dtmax
significantly at stimulation cycle lengths in the range
Figure 3
The concentration-dependent effect of ORM-10103 on the NCX current in canine ventricular myocytes. Each panel presents Ni2+-sensitive (NCX)
current traces before and after superfusion of the cells with a concentration of ORM-10103 ranging from 0.1 to 10 μM.
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300–5000 ms, suggesting that it has no effect on the inward
sodium current (Figure 5B).
As the ICaL measurements exhibited a slight rundown in
some voltage clamp experiments, the effect of ORM-10103
was also studied on slow response action potentials recorded
from guinea pig papillary muscles. As Figure 6 shows, ORM-
10103 at 10 μM did not affect the amplitude (control: 81.2 ±
5.7 mV, ORM-10103: 81.6 ± 6.1 mV, n = 5, n.s.) or dV/dtmax
(control: 12.4 ± 2.3 V·s−1, ORM-10103: 11.8 ± 2.6 V·s−1, n = 5,
n.s.) of these slow response action potentials, suggesting a
lack of effect of ORM-10103 on the ICaL. In the same prepara-
tion, the well-established calcium current blocker nisoldipine
at 50 nM markedly reduced both the amplitude and dV/dtmax
of the slow response action potentials.
On recording outward potassium currents (n = 8–10), we
found that IK1, Ito and IKs were not affected; however, IKr was
slightly but significantly diminished (from 58.6 ± 5.6 pA to
43.1 ± 5.1 pA at 20 mV test potential, n = 8, P < 0.05) in the
presence of 3 μM ORM-10103 (Figure 7).
The Na+/K+ pump current (Ip) was measured as described
in the Methods section. The Ip current was 100.7 ± 14.6 pA in
control conditions and it decreased to 86.7 ± 11.7 pA (13.9%,
n = 6, P < 0.05) at the end of the 5–7 min incubation with
10 μM ORM-10103. During the measurements, a gradual
slight decrease of the steady-state current was observed
(Figure 8A). Therefore, a separate set of experiments was per-
formed when the same protocol was applied but ORM-10103
was not added to the bath solution. Measuring the steady-
state current using the same timescale, compared to the
ORM-10103 experiments, a similar slight current decrease
was recorded (119.7 ± 25.6 pA vs. 92.6 ± 27.6 pA, 22.7%, n =
3, P < 0.05, Figure 8B). Therefore, it was concluded that ORM-
10103 does not influence Ip, the slight tendency of the
current to decrease is not due to the effect of ORM-10103. In
another experiment 10 μM strophanthin, known to block the
Na+/K+ pump, was applied. Strophanthin effectively dimin-
ished the current and 0 K+ solution failed to decrease the
current further showing that the measured current was the
Na+/K+ pump current (Figure 8C).
Effects of ORM-10103 on the EAD and DAD
The effects of ORM-10103 on EAD and DAD were studied in
canine right ventricular papillary muscles and in canine
cardiac Purkinje fibres, respectively, by applying the conven-
tional microelectrode technique.
EAD was evoked in the papillary muscle preparation,
stimulated at slow cycle lengths (1500–3000 ms) with a com-
bination of 1 μM dofetilide and 100 μM BaCl2 (Figure 9A).
Both 3 and 10 μM ORM-10103 clearly decreased the ampli-
tude of the EAD. This effect was concentration-dependent
and reversible upon washout of the ORM-10103 from the
tissue bath containing dofetilide and BaCl2. Similar effects
were seen in additional experiments (Figure 9A, right panel).
ORM-10103 3 μM decreased the amplitude of the EAD from
19.3 ± 2.2 to 11.7 ± 2.4 mV (n = 6, P < 0.05). At 10 μM, the
compound had a somewhat more pronounced effect, decreas-
ing EAD from 19.4 ± 3.3 to 9.5 ± 4.0 mV (n = 4, P < 0.05).
DAD was evoked in Purkinje fibre preparations superfused
with 0.2 μM strophanthin for 40 min (Figure 9B). In these
experiments, a train of 40 stimuli was applied with a cycle
length of 400 ms in the train. The train was then followed by
Figure 4
(A) The amplitude of the inward (left) and the outward (right) NCX currents in the absence or in the presence of 3 μM ORM-10103. Bars indicate
± SEM, *P < 0.05. (B) The concentration–response curve for ORM-10103 on the inward (left) and outward (right) NCX currents in canine
ventricular myocytes at −80 and +20 mV respectively. Values are means ± SEM, n = 3–8.
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a stimulation-free period of 20 s to allow observation of DAD
formation. Following the addition of 3 or 10 μM ORM-10103,
the DAD amplitude was decreased (Figure 9B). This effect
was also concentration-dependent; ORM-10103 at 3 μM
decreased the DAD amplitude from 5.5 ± 0.6 to 2.4 ± 0.8 mV
(n = 6, P < 0.05) while 10 μM ORM-10103 did so from 8.1 ± 2.3
to 2.5 ± 0.3 mV (n = 5, P < 0.05). In the two experiments,
strophanthin evoked a run of extra beats after the termina-
tion of the stimulus train, which could be successfully abol-
ished by the application of 10 μM ORM-10103 (Figure 9C).
Discussion
The main finding of this study is that ORM-10103 effectively
inhibited the NCX current without affecting ICaL, and this
effect was associated with decreases in the amplitudes of EAD
and DAD evoked in canine ventricular papillary muscle and
cardiac Purkinje fibres, respectively. In our experiments, NCX
current is defined as Ni2+-sensitive current. ORM-10103 inhib-
ited INCX in canine ventricular myocytes at relatively low
concentrations, with an estimated EC50 of 780–960 nM. In
Figure 5
(A) Lack of effect of 10 μM ORM-10103 on the L-type ICa and INa assessed as dV/dtmax in canine ventricular myocytes. In the inset at the top, the
voltage protocol is shown. The left panels indicate original current traces recorded in control conditions, in the presence of 10 μM ORM-10103,
after washout of ORM-10103 and after application of 10 μM nifedipine. The right panel illustrates the current–voltage relationship of ICaL in the
absence and presence of 10 μM ORM-10103 after washout of ORM-10103 and after application of 10 μM nifedipine. Values are means ± SEM.
(B) Lack of effect of 10 μM ORM-10103 on the dV/dtmax indicative of INa in canine right ventricular papillary muscles. Values are means ± SEM.
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the same cells, even at the high concentration of 10 μM,
ORM-10103 did not influence ICaL measured by the patch
clamp technique, or INa estimated as dV/dtmax by the
conventional microelectrode measurements. Consequently,
decreases in the inward currents and thereby diminution of
the Ca2+ load via the ICaL and INa cannot explain the effects of
ORM-10103 on the amplitudes of EAD and DAD. ORM-10103
did not induce marked changes in Ito, IK1 and IKs, but a slight
but significant decrease in the IKr was observed in the presence
of ORM-10103. It is of interest that a reduction in outward
Figure 6
Lack of effect of ORM-10103 on slow response action potentials in guinea pig ventricular myocytes. (A) Shows original slow action potential
recordings under control conditions, in the presence of 10 μM ORM-10103 and after application of 50 nM nisoldipine. (B) and (C) reveal the lack
of effect of 10 μM ORM-10103 on the action potential amplitude and on the maximum rate of depolarization (dV/dtmax) respectively.
Figure 7
Effect of ORM-10103 on IK1 (A), Ito (B), IKr (C) and IKs (D). Insets show the applied voltage protocols. Values are means ± SEM, *P < 0.05.
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potassium currents resulting in prolongation of repolariza-
tion would increase rather than decrease the liability to after-
depolarizations (Morissette et al., 2005). Therefore, the
possibility that the rapid delayed rectifier K+ current is
involved in the mechanism whereby ORM-10103 decreases
EAD and DAD is unlikely. The same applies to Ip. Diminishing
Ip would induce rather than reduce DAD. However, our
experiments clearly showed that ORM-10103 did not influ-
ence this current. The possible involvement of other trans-
membrane ionic currents, such as ICl, cannot be completely
ruled out.
To date, two compounds, KB-R7943 and SEA-0400, which
potently inhibit the NCX current even at submicromolar
concentrations have been reported. In addition, KB-R7943
has been shown to abolish experimental arrhythmias
(Watano et al., 1999; Elias et al., 2001), whereas SEA-0400
significantly decreases the pharmacologically-induced EAD
and DAD in canine ventricular preparations at concentra-
tions at which it does not interfere with ICaL (Nagy et al.,
2004). However, other studies have demonstrated that
KB-R7943 and SEA-0400 in micromolar concentrations do
inhibit the ICaL (Tanaka et al., 2002; Birinyi et al., 2005), which
makes the interpretation of their antiarrhythmic effect some-
what uncertain. Our present investigation has provided
further evidence that specific NCX inhibition results in
suppression of triggered arrhythmias in in vitro cardiac
preparations.
The possible therapeutic implications of our study appear
to be rather complex. It is tempting to speculate that the
suppression of EAD and DAD may be antiarrhythmic in both
the ventricles and the atria (Chen et al., 2000) during a Ca2+
overload, as in heart failure, digitalis intoxication, and at the
beginning of atrial flutter and fibrillation, especially when K+
currents have been down-regulated (Yue et al., 1997; van
Wagoner and Nerbonne, 2000) and the NCX current
up-regulated (Studer et al., 1994). It has been proposed that,
on reperfusion after myocardial ischaemia, Ca2+ influx occurs
via NCX in the reverse mode contributing to Ca2+ overload
and the release of Ca2+ from the sarcoplasmic reticulum and
thereby causing cardiac arrhythmias (Levi et al., 1993).
Accordingly, blockade of the reverse mode of the NCX
current may be beneficial.
In conclusion, the present study has provided evidence of
the strong NCX inhibitory activity of ORM-10103 and its
potential to suppress elementary arrhythmogenic phenom-
ena, such as EAD and DAD. Further research is clearly needed
with both in vitro and in vivo methods in order to elucidate
the potential therapeutic targets and, in a wider sense, the
possible beneficial effect of specific NCX inhibition.
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Figure 8
Lack of effect of ORM-10103 on Na+/K+ pump current. (A) Shows a representative experiment in which 10 μM ORM-10103 does not influence
Ip; however, a slight gradual decrease in the current was detected. An original current trace in (B) indicates that the slight gradual current decrease,
similar to that shown in (A), was also observed without addition of ORM-10103. (C) Strophanthin (10 μM) completely blocks Na+/K+ pump
current. Ip was defined as the difference between currents measured in 5 and 0 mM K+ containing solutions. The current traces were recorded at
a steady potential of −30 mV.
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Figure 9
(A) Effects of 3 and 10 μM ORM-10103 (ORM) on the EAD evoked by 1 μM dofetilide + 100 μM BaCl2 in canine right ventricular papillary muscle.
The stimulation cycle length was 2 s. Trace (a) is a control recording. Trace (b) reveals that EAD was elicited by 1 μM dofetilide + 100 μM BaCl2.
In traces (c) and (d), 3 and 10 μM ORM-10103, respectively, were applied in the continuous presence of dofetilide and BaCl2. As shown in trace
(e), after 30 min of washout of ORM-10103, the EAD amplitude was similar to that before the application of ORM-10103. In diagram (f), the
effects of 3 and 10 μM ORM-10103 on the EAD amplitude are seen. Bars represent means ± SEM. (B) The effect of 3 μM ORM-10103 on the DAD
amplitude in canine right ventricular Purkinje fibres. DAD was evoked by a 40 stimulus train with a stimulation cycle length of 400 ms in the
presence of 0.2 μM strophanthin. Trace (a) is a control recording, trace (b) indicates the induction of DAD by 0.2 μM strophanthin, and trace (c)
demonstrates that 3 μM ORM-10103 almost completely abolished DAD in the continuous presence of strophanthin. Diagram (d) depicts the
effects of 3 and 10 μM ORM-10103 on the amplitude of DAD. Bars represent means ± SEM. (C) Effect of ORM-10103 (10 μM) on strophanthin-
induced automaticity in canine right ventricular Purkinje fibres. Trace (a) is a control recording. Spontaneous activity was recorded after a 40
stimulus train with a stimulation cycle length of 400 ms in the presence of 0.2 μM strophanthin (trace b). Application of 10 μM ORM-10103 in
the presence of strophanthin abolished the spontaneous activity (trace c).
BJPORM-10103, a new NCX inhibitor reduces EAD and DAD
British Journal of Pharmacology (2013) 170 768–778 777
Conflict of interest
There are no conflicts of interest.
References
Alexander SPH, Mathie A, Peters JA (2011). Guide to receptors and
channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1):
S1–S324.
Bers DM (2000). Calcium fluxes involved in control of cardiac
myocyte contraction. Circ Res 87: 275–281.
Bers DM (2002). Cardiac excitation−contraction coupling. Nature
415: 198–205.
Birinyi P, Acsai K, Banyasz T, Toth A, Horvath B, Virag L et al.
(2005). Effects of SEA-0400 and KB-R7943 on Na+/Ca2+ exchange
current and L-type Ca2+ current in canine ventricular
cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 372:
63–70.
Chen YJ, Chen SA, Chang MS, Lin CI (2000). Arrhythmogenic
activity of cardiac muscle in pulmonary veins of the dog:
implication for the genesis of atrial fibrillation. Cardiovasc Res 48:
265–273.
Elias CL, Lukas A, Shurraw S, Scott J, Omelchenko A, Gross GJ et al.
(2001). Inhibition of Na+/Ca2+ exchange by KB-R7943: transport
mode selectivity and antiarrhythmic consequences. Am J Physiol
Heart Circ Physiol 281: H1334–H1345.
Hobai IA, Khananshvili D, Levi AJ (1997). The peptide ‘FRCRCFa’,
dialysed intracellularly, inhibits the Na/Ca exchange in rabbit
ventricular myocytes with high affinity. Pflugers Arch 433:
455–463.
Levi A, Brooksby P, Hancox JC (1993). One hump or two? The
triggering of calcium release from the sarcoplasmic reticulum and
the voltage dependence of contraction in mammalian cardiac
muscle. Cardiovasc Res 27: 1743–1757.
Morissette P, Hreiche R, Turgeon J (2005). Drug-induced long QT
syndrome and torsade de pointes. Can J Cardiol 21: 857–864.
Nagy ZA, Virág L, Tóth A, Biliczki P, Acsai K, Bányász T et al.
(2004). Selective inhibition of sodium-calcium exchanger by
SEA-0400 decreases early and delayed afterdepolarization in canine
heart. Br J Pharmacol 143: 827–831.
Pogwizd SM (2003). Clinical potential of sodium−calcium
exchanger inhibitors as antiarrhythmic agents. Drugs 63: 439–452.
Pogwizd SM, Bers DM (2002). Calcium cycling in heart failure: the
arrhythmia connection. J Cardiovasc Electrophysiol 13: 88–91.
Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM (2001).
Arrhythmogenesis and contractile dysfunction in heart failure.
Roles of sodium−calcium exchange, inward rectifier potassium
current, and residual-adrenergic responsiveness. Circ Res 88:
1159–1167.
Roden DM (1996). Antiarrhythmic drugs, Chapter 35. In: Hardman
JG, Limbird LE, Molinoff PB, Ruddon RW (eds). Goodman &
Gilman’s The Pharmacological Basis of Therapeutics. McGraw-Hill:
New York, pp. 839–871.
Studer R, Reinecke H, Bilger J, Eschenhangen T, Bohm M,
Hasenfuss G et al. (1994). Gene expression of the cardiac Na+-Ca2+
exchanger in end-stage human heart failure. Circ Res 75: 443–453.
Tanaka H, Nishimaru K, Aikawa T, Hirayama W, Tanaka Y,
Shigenobu K (2002). Effect of SEA0400, a novel inhibitor of
sodium−calcium exchanger, on myocardial ionic currents. Br J
Pharmacol 135: 1096–1100.
Van Wagoner DR, Nerbonne JM (2000). Molecular basis of electrical
remodeling in atrial fibrillation. J Mol Cell Cardiol 32: 1101–1117.
Venetucci LA, Trafford AW, O’Neill SC, Eisner DA (2007). Na/Ca
exchange: regulator of intracellular calcium and source of
arrhythmias in the heart. Ann N Y Acad Sci 1099: 315–325.
Volders PGA, Vos MA, Szabo B, Sipido KR, Marieke DE, Groot SH
et al. (2000). Progress in the understanding of cardiac early
afterdepolarizations and torsades de pointes: time to revise current
concepts. Cardiovasc Res 46: 376–392.
Watano T, Harada Y, Harada K, Nishimura N (1999). Effect of
Na+/Ca2+ exchange inhibitor, KB-R7943 on ouabain-induced
arrhythmias in guinea-pigs. Br J Pharmacol 127: 1846–1850.
Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S (1997). Ionic
remodeling underlying action potential changes in a canine model
of atrial fibrillation. Circ Res 81: 512–525.
BJP N Jost et al.
778 British Journal of Pharmacology (2013) 170 768–778
